BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114:874-883. [PMID: 30908297 DOI: 10.14309/ajg.0000000000000183] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 33.5] [Reference Citation Analysis]
Number Citing Articles
1 Allen PB, Bonovas S, Danese S, Peyrin-Biroulet L. Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. Expert Opin Biol Ther 2020;20:151-61. [PMID: 31815548 DOI: 10.1080/14712598.2020.1702020] [Reference Citation Analysis]
2 D'Arcangelo G, Aloi M. Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say? Paediatr Drugs 2020;22:463-72. [PMID: 32572841 DOI: 10.1007/s40272-020-00406-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kessel C, Lavric M, Weinhage T, Brueckner M, de Roock S, Däbritz J, Weber J, Vastert SJ, Foell D. Serum biomarkers confirming stable remission in inflammatory bowel disease. Sci Rep 2021;11:6690. [PMID: 33758351 DOI: 10.1038/s41598-021-86251-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Barnes EL, Jiang Y, Kappelman MD, Long MD, Sandler RS, Kinlaw AC, Herfarth HH. Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. Inflamm Bowel Dis 2020;26:1225-31. [PMID: 31634390 DOI: 10.1093/ibd/izz247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, Fumery M, Bouguen G, Peyrin-Biroulet L, Bourreille A, Caillo L, Simon M, Goutorbe F, Laharie D. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Aliment Pharmacol Ther 2020;51:852-60. [PMID: 32201971 DOI: 10.1111/apt.15680] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
6 Sagami S, Kobayashi T, Aihara K, Umeda M, Morikubo H, Matsubayashi M, Kiyohara H, Nakano M, Ohbu M, Hibi T. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. Aliment Pharmacol Ther 2020;51:1373-83. [PMID: 32383166 DOI: 10.1111/apt.15767] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
7 Drescher H, Lissoos T, Hajisafari E, Evans ER. Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers. The Journal for Nurse Practitioners 2019;15:676-81. [DOI: 10.1016/j.nurpra.2019.07.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
8 Uździcki AW, Wawrzynowicz-Syczewska M. Characteristic features of ulcerative colitis with concomitant primary sclerosing cholangitis. Prz Gastroenterol 2021;16:184-7. [PMID: 34584578 DOI: 10.5114/pg.2021.108983] [Reference Citation Analysis]
9 Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Li C, Wang J, Ma R, Li L, Wu W, Cai D, Lu Q. Natural-derived alkaloids exhibit great potential in the treatment of ulcerative colitis. Pharmacol Res 2021;175:105972. [PMID: 34758401 DOI: 10.1016/j.phrs.2021.105972] [Reference Citation Analysis]
11 Fujita Y, Tominaga K, Tanaka T, Sugaya T, Yoshihara S. Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer. BMC Gastroenterol 2021;21:424. [PMID: 34758726 DOI: 10.1186/s12876-021-02010-1] [Reference Citation Analysis]
12 Pérez de Arce E, Quera R, Quigley EMM. The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. Gastroenterol Clin North Am 2021;50:689-711. [PMID: 34304795 DOI: 10.1016/j.gtc.2021.03.008] [Reference Citation Analysis]
13 Nuñez F P, Quera R, Sepúlveda E, Simian D, Pizarro G, Lubascher J, Flores L, Ibañez P, Figueroa C, Kronberg U. Pregnancy in Inflammatory Bowel Disease: Experience of a Chilean cohort. Gastroenterol Hepatol 2021;44:277-85. [PMID: 33745519 DOI: 10.1016/j.gastrohep.2020.08.005] [Reference Citation Analysis]
14 Hanioka Y, Shimizu K, Yamagami K, Yao S, Nakamura R, Nakamura T, Goto H. Exacerbation of Ulcerative Colitis with Tocilizumab: A Report of Two Cases, One with Takayasu Arteritis and the Other with Relapsing Polychondritis. Intern Med 2021;60:1615-20. [PMID: 33281154 DOI: 10.2169/internalmedicine.5215-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, Danese S. 'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. Curr Drug Targets 2021;22:117-25. [PMID: 32718289 DOI: 10.2174/1389450121666200727120305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology 2020;159:2052-64. [PMID: 32853634 DOI: 10.1053/j.gastro.2020.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
17 Wei W, Zhang Y, Li R, Cao Y, Yan X, Ma Y, Zhang Y, Yang M, Zhang M. Oral Delivery of Pterostilbene by L-Arginine-Mediated “Nano-Bomb” Carrier for the Treatment of Ulcerative Colitis. IJN 2022;Volume 17:603-16. [DOI: 10.2147/ijn.s347506] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Magro F, Estevinho MM, Dias CC, Correia L, Lago P, Ministro P, Portela F, Feakins R, Danese S, Peyrin-Biroulet L. Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. J Crohns Colitis 2021;15:551-66. [PMID: 32898223 DOI: 10.1093/ecco-jcc/jjaa176] [Reference Citation Analysis]
19 Luo Y, Liu S, Li H, Hou J, Lin W, Xu Z, Lu T, Li Y, Peng B, Zhang S, Han X, Kuang Z, Wen Y, Cai J, Liu F, Chen X. Mass Cytometry and Single-Cell Transcriptome Analyses Reveal the Immune Cell Characteristics of Ulcerative Colitis. Front Mol Biosci 2022;9:859645. [DOI: 10.3389/fmolb.2022.859645] [Reference Citation Analysis]
20 Takishima K, Maeda Y, Ogata N, Misawa M, Mori Y, Homma M, Nemoto T, Miyata Y, Akimoto Y, Mochida K, Takashina Y, Tanaka K, Ichimasa K, Nakamura H, Sasanuma S, Kudo T, Hayashi T, Wakamura K, Miyachi H, Baba T, Ishida F, Ohtsuka K, Kudo SE. Beyond complete endoscopic healing: Goblet appearance using an endocytoscope to predict future sustained clinical remission in ulcerative colitis. Dig Endosc 2021. [PMID: 34816494 DOI: 10.1111/den.14202] [Reference Citation Analysis]
21 Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC; Scientific Workshop Steering Committee . Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. J Crohns Colitis 2021;15:1431-42. [PMID: 33730756 DOI: 10.1093/ecco-jcc/jjab050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Vasant DH, Ford AC. Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift? World J Gastroenterol 2020; 26(26): 3712-3719 [PMID: 32774052 DOI: 10.3748/wjg.v26.i26.3712] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Sánchez-Garrido AI, Prieto-Vicente V, Blanco-Gozalo V, Arévalo M, Quiros Y, López-Montañés D, López-Hernández FJ, Rodríguez-Pérez A, López-Novoa JM. Preventive Effect of Cardiotrophin-1 Administration before DSS-Induced Ulcerative Colitis in Mice. J Clin Med 2019;8:E2086. [PMID: 31805674 DOI: 10.3390/jcm8122086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 D'Amico F, Guillo L, Baumann C, Danese S, Peyrin-Biroulet L. Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis. J Crohns Colitis 2021:jjab063. [PMID: 33822915 DOI: 10.1093/ecco-jcc/jjab063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Li R, Cheng L, Wang Q, Zhou L. Comparative Transcriptomic Analysis Reveals the Immunosuppressive Targets of Mesalazine in Dextran Sulfate Sodium-Induced Ulcerative Colitis. Front Genet 2021;12:698983. [PMID: 34456974 DOI: 10.3389/fgene.2021.698983] [Reference Citation Analysis]
26 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Pabari RM, Tambuwala MM, Lajczak-McGinley N, Aljabali A, Kirby BP, Keely S, Ramtoola Z. Novel polyurethane based particulate formulations of infliximab reduce inflammation in DSS induced murine model of colitis - A preliminary study. Int J Pharm 2021;604:120717. [PMID: 34015378 DOI: 10.1016/j.ijpharm.2021.120717] [Reference Citation Analysis]
28 Su S, Wang X, Xi X, Zhu L, Chen Q, Zhang H, Qin Y, Yang B, Che N, Cao H, Zhong W, Wang B. Phellodendrine promotes autophagy by regulating the AMPK/mTOR pathway and treats ulcerative colitis. J Cell Mol Med 2021;25:5707-20. [PMID: 34002930 DOI: 10.1111/jcmm.16587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Cushing KC, Tan W, Alpers DH, Deshpande V, Ananthakrishnan AN. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Aliment Pharmacol Ther 2020;51:347-55. [PMID: 31696961 DOI: 10.1111/apt.15568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
30 Barsky M, Meserve J, Le H, Collins A, Singh S, Boland B, Sandborn WJ, Dulai PS. Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci 2021;66:2564-9. [PMID: 32875527 DOI: 10.1007/s10620-020-06568-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastro 2019;17:435-48. [DOI: 10.1007/s11938-019-00249-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Kanazawa M, Tominaga K, Yamamiya A, Tanaka T, Watanabe S, Sugaya T, Abe K, Kanamori A, Arisaka T, Hoshi K, Iijima M, Goda K, Haruyama Y, Irisawa A. Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission. Healthcare (Basel) 2021;9:1405. [PMID: 34828451 DOI: 10.3390/healthcare9111405] [Reference Citation Analysis]
34 Aniwan S, Limsrivilai J, Pongprasobchai S, Pausawasdi N, Prueksapanich P, Kongtub N, Rerknimitr R. Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018. Intest Res 2021;19:186-93. [PMID: 32806871 DOI: 10.5217/ir.2020.00028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
35 Denesh D, Carbonell J, Kane JS, Gracie D, Selinger CP. Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. Expert Rev Gastroenterol Hepatol 2021;15:1091-6. [PMID: 33653185 DOI: 10.1080/17474124.2021.1898944] [Reference Citation Analysis]
36 Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin 2021;37:1891-900. [PMID: 34404286 DOI: 10.1080/03007995.2021.1968813] [Reference Citation Analysis]
37 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 26.0] [Reference Citation Analysis]
38 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
39 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
40 Molander P, Kemppainen H, Ilus T, Sipponen T. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. Scand J Gastroenterol 2020;55:34-40. [PMID: 31841064 DOI: 10.1080/00365521.2019.1701070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Kichloo A, El-Amir Z, Dahiya DS, Wani F, Shaka H. Trends in hospitalizations and mortality for inflammatory bowel disease from a nationwide database study between 2008 and 2018. Proc (Bayl Univ Med Cent) 2021;34:550-4. [PMID: 34456471 DOI: 10.1080/08998280.2021.1919009] [Reference Citation Analysis]
42 Ercan G, Yigitturk G, Erbas O. Therapeutic effect of adenosine on experimentally induced acute ulcerative colitis model in rats. Acta Cir Bras 2020;34:e201901204. [PMID: 32074166 DOI: 10.1590/s0102-865020190120000004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Bezzio C, Vernero M, Ribaldone DG, Manes G, Saibeni S. Insights into the role of gastrointestinal ultrasound in ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211051456. [PMID: 34707688 DOI: 10.1177/17562848211051456] [Reference Citation Analysis]
44 Modi NB, Cheng X, Mattheakis L, Hwang CC, Nawabi R, Liu D, Gupta S. Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers. Clin Pharmacol Drug Dev 2021. [PMID: 33942566 DOI: 10.1002/cpdd.946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Gong M, Zhang F, Miao Y, Niu J. Advances of Heat Shock Family in Ulcerative Colitis. Front Pharmacol 2022;13:869930. [DOI: 10.3389/fphar.2022.869930] [Reference Citation Analysis]
46 Arkteg CB, Goll R, Gundersen MD, Anderssen E, Fenton C, Florholmen J. Mucosal gene transcription of ulcerative colitis in endoscopic remission. Scand J Gastroenterol 2020;55:139-47. [PMID: 31918598 DOI: 10.1080/00365521.2019.1710245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Capecchi R, Migliorini P, Zanzi F, Maltinti S, Puxeddu I, de Bortoli N, Bellini M, Costa F, Marchi S, Bertani L. Ig Glycosylation in Ulcerative Colitis: It's Time for New Biomarkers. Front Pharmacol 2021;12:654319. [PMID: 33897440 DOI: 10.3389/fphar.2021.654319] [Reference Citation Analysis]
48 Husam Al-Ani A, Christensen B. Endoscopic and histologic endpoints as treatment targets: Are we there yet? J Gastroenterol Hepatol 2021;36 Suppl 1:8-9. [PMID: 33817841 DOI: 10.1111/jgh.15447] [Reference Citation Analysis]
49 Knyazev OV, Khomeriki SG, Kagramanova АV, Lishchinskaya AA, Smirnova OA, Noskova KK, Parfenov AI. Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy. Terapevticheskii arkhiv 2022;93:1435-42. [DOI: 10.26442/00403660.2021.12.201212] [Reference Citation Analysis]
50 Magro F, Estevinho MM. Do Neutrophils Contribute to Development of Crohn’s Disease and Ulcerative Colitis? Clinical Gastroenterology and Hepatology 2020;18:2430-1. [DOI: 10.1016/j.cgh.2020.01.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Knyazev OV, Kagramanova AV, Khomeriki SG, Parfenov AI. Is histological remission of ulcerative colitis achievable? Terapevticheskii arkhiv 2021;93:975-81. [DOI: 10.26442/00403660.2021.08.200981] [Reference Citation Analysis]
53 Shaffer SR, Erondu AI, Traboulsi C, Rai V, Krugliak Cleveland N, Israel A, Christensen B, Rubin DT. Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. Inflamm Bowel Dis 2021:izab130. [PMID: 34037230 DOI: 10.1093/ibd/izab130] [Reference Citation Analysis]
54 Friedman AB, Asthana A, Knowles SR, Robbins A, Gibson PR. Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease. Aliment Pharmacol Ther 2021;54:652-66. [PMID: 34157157 DOI: 10.1111/apt.16452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Rao K, Qin S, Yang Y, Zhan K, Wu H, Zheng H, Huang S. Shenling Baizhu Powder Alleviates TNBS-Induced Colitis in Rats by Improving Intestinal Epithelial Permeability and Inhibiting Inflammation Through the TLR5/MyD88/NF-κB Pathway. Front Pharmacol 2022;13:883918. [DOI: 10.3389/fphar.2022.883918] [Reference Citation Analysis]
56 Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Front Med (Lausanne) 2021;8:737256. [PMID: 34604268 DOI: 10.3389/fmed.2021.737256] [Reference Citation Analysis]
57 Pérez de Arce E, Quera R, Beltrán CJ, Madrid AM, Nos P. Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis? Gastroenterol Hepatol 2021:S0210-5705(21)00143-6. [PMID: 34023477 DOI: 10.1016/j.gastrohep.2021.02.022] [Reference Citation Analysis]
58 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:420-33. [PMID: 31352659 DOI: 10.1007/s11938-019-00244-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opin Biol Ther 2020;20:407-12. [PMID: 31847610 DOI: 10.1080/14712598.2020.1701652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
60 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2021:izab228. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Reference Citation Analysis]
61 Jefferson K. Living with Crohn's: A Personal Account. J Christ Nurs 2020;37:E1-3. [PMID: 31809388 DOI: 10.1097/CNJ.0000000000000689] [Reference Citation Analysis]
62 Wu Y, Liu X, Li G. Integrated bioinformatics and network pharmacology to identify the therapeutic target and molecular mechanisms of Huangqin decoction on ulcerative Colitis. Sci Rep 2022;12:159. [PMID: 34997010 DOI: 10.1038/s41598-021-03980-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
63 Núñez F P, Krugliak Cleveland N, Quera R, Rubin DT. Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. World J Gastroenterol 2021; 27(20): 2521-2530 [PMID: 34092973 DOI: 10.3748/wjg.v27.i20.2521] [Reference Citation Analysis]
64 Takenaka K, Fujii T, Kawamoto A, Suzuki K, Shimizu H, Maeyashiki C, Yamaji O, Motobayashi M, Igarashi A, Hanazawa R, Hibiya S, Nagahori M, Saito E, Okamoto R, Ohtsuka K, Watanabe M. Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00372-1. [PMID: 34856196 DOI: 10.1016/S2468-1253(21)00372-1] [Reference Citation Analysis]
65 Narula N, Wong ECL, Colombel JF, Riddell R, Marshall JK, Reinisch W, Dulai PS. Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00716-3. [PMID: 34229037 DOI: 10.1016/j.cgh.2021.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
66 Arkteg CB, Wergeland Sørbye S, Buhl Riis L, Dalen SM, Florholmen J, Goll R. Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One 2021;16:e0248224. [PMID: 33684168 DOI: 10.1371/journal.pone.0248224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Dignass AU, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Travis SPL. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scand J Gastroenterol 2021;:1-8. [PMID: 34932423 DOI: 10.1080/00365521.2021.2015801] [Reference Citation Analysis]
68 Pandey A, Achrafie L, Kodjamanova P, Tencer T, Kumar J. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, economic and quality-of-life outcomes. Curr Med Res Opin 2022;:1-40. [PMID: 35608153 DOI: 10.1080/03007995.2022.2081453] [Reference Citation Analysis]
69 Dulai PS, Jairath V. How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission? Clin Gastroenterol Hepatol. 2020;18:1300-1308. [PMID: 31887449 DOI: 10.1016/j.cgh.2019.12.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
70 Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance.Nat Rev Gastroenterol Hepatol. 2020;17:1-2. [PMID: 31520081 DOI: 10.1038/s41575-019-0211-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
71 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Reference Citation Analysis]
72 Selinger C, Carbonell J, Kane J, Omer M, Ford AC. Acceptability of a 'treat to target' approach in inflammatory bowel disease to patients in clinical remission. Frontline Gastroenterol 2021;12:30-8. [PMID: 33493249 DOI: 10.1136/flgastro-2019-101366] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Honig G, Larkin PB, Heller C, Hurtado-Lorenzo A. Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S1-S16. [PMID: 34791292 DOI: 10.1093/ibd/izab230] [Reference Citation Analysis]
74 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Beaugerie L, Ricart E, Dewit O, Lopez-sanroman A, Fumery M, Carbonnel F, Buisson A, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Peyrin-biroulet L, Mary J. Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clinical Gastroenterology and Hepatology 2021;19:1180-1188.e4. [DOI: 10.1016/j.cgh.2020.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
75 Helwig U, Fischer I, Hammer L, Kolterer S, Rath S, Maaser C, Kucharzik T. Transmural Response and Transmural Healing Defined by Intestinal Ultrasound - New Potential Therapeutic Targets? J Crohns Colitis 2021:jjab106. [PMID: 34185843 DOI: 10.1093/ecco-jcc/jjab106] [Reference Citation Analysis]
76 Matsubayashi M, Kobayashi T, Okabayashi S, Nakano M, Sagami S, Ozaki R, Kiyohara H, Morikubo H, Asonuma K, Miyatani Y, Maeda S, Hibi T. Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. J Gastroenterol Hepatol 2021;36:943-50. [PMID: 32805065 DOI: 10.1111/jgh.15220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Srinivasan A, van Langenberg DR, Little RD, Sparrow MP, De Cruz P, Ward MG. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn’s disease. Aliment Pharmacol Ther 2020;51:1342-52. [DOI: 10.1111/apt.15742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
78 Queiroz NSF, Teixeira FV, Parra RS, Kotze PG. INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE. Arq Gastroenterol 2020;57:507-10. [PMID: 33331484 DOI: 10.1590/S0004-2803.202000000-76] [Reference Citation Analysis]
79 Kader R, Dart RJ, Sebepos‐rogers G, Shakweh E, Middleton P, Mcguire J, Pavlidis P, Ahmad OF, Segal J, Samaan MA, Gahir J, Black G, Theaker H, Calderbank T, Meade S, Ibraheim H, Clough J, Bancil A, Honap S, Hampal R, Tavabie O, Tai C, Tern P, Akbar S, Patel R, Rhead C, Kabir M, Bashyam M, Fofaria R, Hiner G, Ravindran S, Walton H, King J, Dhillon A, Seller P, Mukherjee S, Harlow C; GLINT Research Network. Implementation of an intervention bundle leads to quality improvement in ulcerative colitis endoscopy reporting. GastroHep 2020;2:309-17. [DOI: 10.1002/ygh2.427] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]